STAT
JANUARY 10, 2024
This latest revision, known as the DSM-5-TR, was prepared between 2016 and 2019, and published in 2022. The researchers found that, of the 55 physicians with ties to a pharmaceutical company, 91% accepted food and beverages, and 69% received compensation for travel and consulting, according to the analysis published in the BMJ.
STAT
OCTOBER 25, 2023
Oncologists were more likely to provide low-value cancer care after receiving money from pharmaceutical companies, and the findings raise questions about the extent to which industry influence may have led to patient harm, according to a new study. Continue to STAT+ to read the full story…
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
JULY 17, 2024
Senate had achieved a breakthrough in the battle to prevent pharmaceutical companies from abusing the patent system, an issue that has been blamed for boosting prescription drug costs for Americans. John Cornyn (R-Texas), boasted that the bill, which was first introduced in May 2019 , would thwart the use of so-called patent thickets.
European Pharmaceutical Review
OCTOBER 5, 2022
Pharmaceutical companies who contributed to the survey include AbbVie, AstraZeneca, Boehringer Ingelheim and GSK. The survey also acknowledged more people are pursuing higher apprenticeship qualifications at Bachelor and Master degree level, which is double the number of level 6 and 7 apprenticeships done in 2019.
STAT
JUNE 25, 2024
Pharmaceutical companies in the U.K. Between 2004 to 2021, the Prescription Medicines Code of Practice Authority, a self-regulatory body overseen by the Association of the British Pharmaceutical Industry, ruled on more than 1,100 cases involving nearly 160 companies where there was a breach of the industry code.
Pharmaceutical Technology
MAY 10, 2023
This marks a significant development in a tumultuous dispute between the pharmaceutical company and the US government. In November 2019, the government sued Gilead over the company’s alleged patent infringement of the two PrEP drugs Descovy and Truvada. Gilead markets both Truvada and its successor Descovy.
STAT
DECEMBER 7, 2023
In 1997, Celgene obtained a key patent for what would become a blockbuster blood cancer treatment, giving it a monopoly until 2019. But like any pharmaceutical company with an eye toward the future, Celgene continued to seek other ways to wring profits from its development work.
Expert insights. Personalized for you.
145 
Let's personalize your content